Pharmacological inhibition of AKT reduces the survival of CLL cells ex vivo under standard conditions [31, 33], indicating that AKT inhibitors may have therapeutic potential in CLL. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.